NASA Bets on Two Rockets to One Destination
Published on 20 September 2026
Read article
Listen to article
6:06Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
For years, I’ve looked at smartwatches as little more than glorified pedometers for the perpetually anxious. They tell you the time, buzz when you get an email, and gently nudge you to stand up when you’ve been enjoying a pint for too long. Useful, perhaps, but hardly revolutionary. But something just changed. When American regulators gave Apple the nod for its hypertension monitoring feature, the smartwatch quietly graduated from a lifestyle gadget to a serious medical instrument. And for investors, that changes everything.
Let’s be clear, this isn’t just another software update. The FDA’s clearance is a watershed moment. It’s the official stamp of approval that says the device on your wrist can be trusted with your health. Think about it. Hypertension, or high blood pressure, is a silent killer affecting nearly half the world's adults. Most people don’t even know they have it. Traditionally, you’d need a trip to the GP or a clunky cuff at home to check it. Now, a device you wear every day could monitor it continuously.
This is the critical shift. We are moving from reactive healthcare, where we only see a doctor when something is broken, to a proactive model. This little device could spot a problem months or even years before it becomes a full-blown crisis. It’s a fundamental change in how we manage health, and the companies enabling this shift are sitting on a potential goldmine.
Of course, Apple grabs the headlines. They always do. But to think this is just an Apple story is to miss the point entirely. The real opportunity, I think, lies in the sprawling ecosystem that supports this revolution. While Apple provides the slick consumer-facing gadget, other, less glamorous companies are building the essential plumbing.
Take a company like Medtronic. They’ve been in the serious medical technology game for decades, long before anyone thought of putting a computer on their wrist. Their expertise in creating regulated, clinically-proven devices makes them a crucial player as wearables become more medically focused. Then you have firms like ResMed, which specialises in connecting patients and doctors remotely. They are perfectly positioned to manage the torrent of data these new devices will unleash. It’s not about one company winning, it’s about an entire industry levelling up.
The real value here isn't in the one-off sale of a watch. It's in the data. The continuous, long-term health data that has never been accessible before. This information is incredibly valuable to healthcare providers, insurance companies, and pharmaceutical researchers. The companies that can successfully build the platforms to analyse and monetise this data are the ones that could see sustained growth.
This, however, makes it a wonderfully complex field for an investor. It’s not a simple case of backing the most popular brand. You have hardware makers, sensor specialists, software platforms, and telehealth providers all vying for a piece of the pie. To me, the real challenge is figuring out where the value will truly accumulate. It's a classic case of Wearable Health Stocks: Growth Potential vs Competition, where picking a single winner is a fool's errand. Investing here requires a broader view, acknowledging the risks of regulation and data privacy, but also recognising the immense demographic tailwinds of an ageing global population.
View the full Basket:Wearable Health Stocks: Growth Potential vs Competition
View the full Basket:Wearable Health Stocks: Growth Potential vs Competition
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 20 September 2026
Read article
Published on 20 September 2026
Read article
Published on 19 September 2026
Read article
Published on 19 September 2026
Read article
Published on 18 September 2026
Read article